OWC Pharmaceutical Research Corp (OTCMKTS:OWCP) And STENOCARE Sign An MOU

OWC Pharmaceutical Research Corp (OTCMKTS:OWCP) and STENOCARE are into a new progressive deal. The two business giants just moved into a Memorandum of Understanding (MoU) that is quite strategic. These two seek to engage in the development and the commercialization of some wide-ranging cannabis-based medical products.

Terms of the deal

Each of the parties will have something to gain from the deal. For instance, OWC’s technologies will benefit from a more expansive market. On the other hand, the business strategy of STENOCARE might end up becoming a huge success. The business guru has been looking forward to supplementing its top-quality generic medical cannabis products. Its target has been to supplement them with differentiated products meant to treat numerous patient groups struggling with particular serious conditions.

The new cooperation means well for them, considering that they will increase their sales massively. They will also be able to distribute products in large volumes within the existing core markets of STENOCARE. The businesses also want to venture into new territories in their quest to boost their business profits.

STENOCARE and its plans

STENOCARE expresses its willingness to deliver some top quality cannabis raw materials. Asides from that, it will also be seeking to provide extensive knowledge in line with the supply and the distribution of the medical cannabis-based products in Ireland and Denmark as well.

On the other hand, OWC Pharmaceutical says it will offer its expertise in clinical trials and medical research. The business has been focusing on cannabis products providing therapeutic solutions to patients. It prides itself on having in place what it terms an extensive Intellectual Property Portfolio.

The first product candidate

The information regarding the first product candidate for this collaboration is already out. This will be a sublingual tablet pulling along with specified medical cannabis ratios vital in meeting up to the needs of patients. It will be important to make the appropriate diagnosis as well as check out how they will be responding to treatment.

The CEO of OWC Pharmaceutical Research Mordechai Bignitz says that STENOCARE is a great choice for a partner. He says that considering the company’s capacity in the distribution of medical cannabis products to some interesting markets. This official also speaks about the focus on pharma-grade production.


OWC Pharmaceutical Research Corp (OTCMKTS:OWCP) Announces Positive Safety Results From The First Phase Study For Medical Cannabis Ointment For Skin Disease Treatment

OWC Pharmaceutical Research Corp (OTCMKTS:OWCP) has announced positive safety data for the first phase study of the medical grade cannabis ointment in treating skin diseases.

Preliminary results indicate that there were no severe adverse effects observed in the safety study. OWC Pharmaceuticals is on track to commence the second phase MSG ointment trial by the third quarter of 2019 in the treatment of psoriasis.

The first phase study was a single center, placebo-controlled trial for the assessment of tolerability and safety of the Cannabis MGC ointment in healthy subjects. The ointment has 3% THC and 3% CBD components. The study was carried out in Israel at the Sheba Academic Medical Centre from September 2017 when the first subject was enrolled in the study until January this year when the last subject concluded the trial.

Stages of the study

The first stage was designed for the evaluation of safety and tolerability after a single dose administration of MGC ointment 26 volunteers. The subjects got hospitalized and they were monitored 24 hours.

The second stage was equally designed to evaluate the safety and tolerability of the MGC ointment after repeated application in 20 volunteers for almost six weeks. The second stage enrolled 7 new subjects in addition to 20 of those who participated in the first stage. The application of the MSG ointment was to be done by the subjects at home twice each day. The subjects were to apply the MGC ointment on one arm and then the MSG on the other placebo arm.

No adverse effects from MSG and MGC ointment

There were no adverse events reported in the two stages of the study although one subject reported minor irritations.

CEO Mordechai Bignizt indicated that they were motivated by the positive results from the first phase of the trial. He added that this was the first study that evaluated the safety and tolerability of their medical grade cannabis ointment as a topical skin disease treatment.

The second phase of the trial of MSC ointment will commence in the Q3 2019 for treatment of psoriasis.


OWC Pharmaceutical Research Corp (OTCMKTS:OWCP) Issues Chairman’s Statement to Shareholders

The Owc Pharmaceutical Research Corp. (OTCMKTS:OWCP) which a leading developer of cannabinoid based therapies that targets a large variety of condition and disorders medicines.

The company is willing and committed in structuring itself as a leader in the cannabis medical market and to improve its patients’ lives by development of a new solution together with devices and other products.

New Events

The products are said to have been derived from mechanisms that are used in the delivery of cannabis in the medical sector.

The company has recruited a high number of skilled managers in their team who have an experience in the cannabis medical sector, pharmaceutical development and management of cooperatives in togetherness with the capital markets. In a statement the company indicated that it is not a member of the pact that had recently been signed.

The chief executive officer of the company in a statement given to newsrooms said that it is aimed at developing the programs, which are set to be rolled out by the organization in few months to come.

Safety Tests

In the program there is safety test for the cannabis cream that is inter alia. The process to be approved needs an initiative safety trial for all the tablets and other pipeline projects to be added. The company is said to be gearing toward the improvement of the shareholders stake through a professional, ethical and management strategy.

With all these put in place the company has continued to offer better and high quality products to its existing and upcoming customers. There are also some changes which will be put in place in the management of the company to reduce chances of a fallout. The management also stated that it was committed to development programs.

Dr. Stanley Hirsch, the company’s chairman attributed to the fact that the management was committed to building value for its shareholders through strategic, professional and ethical management that is believed to bring improved health and quality of life to patients around the world.


OWC Pharmaceutical Research Corp (OTCMKTS:OWCP) Topical Cream In Focus

OWC Pharmaceutical Research Corp (OTCMKTS:OWCP) has obtained expressions of interest from the medical and scientific communities globally as a result of its recently reported positive initial clinical efficacy tests data of its topical cream targeting Psoriasis.

The details

OWC Pharmaceutical’s scientific team, directed by the famous Dr. Yehuda Baruch, the firm’s Chief Science Officer previously released trial data and stated that post-application of company’s unique, active CBD-based topical cream, they recorded up to 70% improvement in many inflammation markers directly linked with Psoriasis.

This promising data have led them to expand the scope and size of its clinical study and has resulted in directly to receipt of continuing queries and expressions of interest from investigators world-wide for more data on its topical cream for psoriasis treatment and their product’s expected availability for application in the market.

OWC Pharmaceutical actively protects its IP. It will report the final data, clinical data and relevant protocols after the closure of the full bio-data IP protection. Ziv Turner, the Managing Director of OWC Pharmaceutical, commented that as soon as they closed the efficacy results of their pre-clinical psoriasis cure, the company has continued to get active inquiries from many global scientific institutions in nations like Germany, Hungary, the Czech Republic, and more, that adopted or plan to adopt MMJ bills.

The company is in talks for marketing and scientific cooperation deals. In addition, they realistically anticipate product readiness for their topical cream in initial Q3 2017 and, based on regulatory approvals, states and federal laws they can offer their product to psoriasis patients.

Psoriasis comes in the list of autoimmune diseases, and a patient with psoriasis gets red, scaly patches on the skin. The disease can be related with other grave health conditions, including heart disease, depression and diabetes. Skin cells in psoriasis patients grow at an unusually fast rate, triggering a buildup of lesions that burn and itch.


CFN Media Interviews OWC Pharmaceutical Research Corp (OTCMKTS:OWCP) CSO

CFN Media Group, the major digital media and creative agency network committed to legal cannabis, reported the issue of an article and interview with OWC Pharmaceutical Research Corp (OTCMKTS:OWCP) CSO Dr. Yehuda Baruch. The interview emphases on Dr. Baruch’s remarkable background in cannabis research, the firm’s clinical trial plan, and the general prospects for cannabis as a drug.

The buzz

OWC Pharmaceutical owns 100% of its subsidiary unit One World Cannabis Ltd. The latter was established to lay pharmaceutical research protocols as well as disciplines to the international medical cannabis market. Dr. Baruch spearheads the firm’s research measures after being the head of the Medical Cannabis Program for more than 10 years, managing regulatory compliance, clinical trials and other industry-wide problems.

OWC Pharmaceuticals is concentrated on the advancement of two delivery plans: A proprietary, CBD-enriched sublingual tablet and an exclusive topical compound. Besides these, the firm intends to address numerous multi-billion-dollar end industries counting grave medical ailments such as multiple myeloma, fibromyalgia, psoriasis and post-traumatic stress disorder, along with hundreds of increased addressable indications in the coming period.

OWC Pharmaceuticals reported the advancement of a proprietary, CBD-enriched sublingual tablet for medical cannabis in the last October. The tablet was advanced to surge the bioavailability of CBDs and offer an optimal administration process for consistent dosing. OWC Pharmaceuticals intends to advance the tablet to cure conditions like post-traumatic stress disorder, fibromyalgia and multiple myeloma.

Prior to releasing the tablet, the firm closed in-vitro testing of a CBD-based offering for multiple myeloma in March 2016. The company’s management intends to proceed with pre-clinical studies approved by the IRB to duplicate that outcome in mice before progressing with human studies. The in-vitro testing demonstrated 100% malignant cell death in as much as 60% of diseased mice cells, promising report.

OWC Pharmaceuticals produced a topical CBD-based cream for the cure of psoriasis in association with one of Israel’s leading cosmetic manufacturers, Emilia Cosmetics Ltd. in March 2016.


OWC Pharmaceutical Research Corp (OTCMKTS:OWCP) To Commence Safety Testing On Its CBD-Infused Cream

OWC Pharmaceutical Research Corp (OTCMKTS:OWCP) an Israeli-based developer of CBD-based treatments targeting numerous different medical ailments and disorders reported that it has obtained Institutional Review Board approval to perform safety testing on its patented topical crème compound for the cure of psoriasis and related skin problems. The approval comes after the firm’s February 1, 2017 8K filing reporting an extension to the scope and size of its efficacy trial on the same compound, which commenced in November 2016.

The details

The IRB approved trial covers the cream itself, as a delivery mode, as well as the psoriasis formulation, and is the first to officially make such assertions with the NIH Registry. The trial, which will be done on healthy volunteers at an Israel’s pioneer academic hospitals, is intended to show the safety of the formulation in curing psoriasis on human skin tissue. Managers started soliciting for trial participants as soon as nod was obtained.

Dr. Yehuda Baruch of OWC Pharmaceutical, reported that this nod is an important milestone for company, where their objective is to follow the same rigorous plan common to traditional pharmaceutical advancement to the medical cannabis segment. As posted earlier this year, the report of the efficacy trials was so promising that management determined it was in their interest to extend the scope and size of the trial to assess the biological markers generated to date, among other things.

Dr. Baruch added with each trial they perform, the ability of their formulation to offer relief for psoriasis-linked indications to people suffering from the condition are validated. The trial that was just accepted was intended to assure caregivers and patients that it is safe to utilize outside of lab conditions.

As soon as the company reported the formulation of psoriasis treatment they started getting requests for the product from people suffering from the condition.

Pin It on Pinterest